MGI Tech Co., Ltd. researches, develops, produces, and sells instruments, reagents, and related products for precision medicine, agriculture, healthcare, and other industries in China and internationally. Its offerings include DNBSEQ and cycloneSEQ sequencers and sequencing consumables; generative lab intelligence products such as sample pretreatment, nucleic acid extraction, universal pipetting, integrated platforms, an intelligent digital platform, and sample preparation; and Multi-Omics products covering cell omics, STOmics, proteomics, PopOmics, sample preparation reagents, microbiomics, agriculture and food safety, public health, environment and biodiversity, ultrasound, bio-fragment analyzers, sample storage, and fluorometers. The company was founded in 2016 and is headquartered in Shenzhen, China.
MGI Tech surges 22.24% in four days as the AI drug discovery picks-and-shovels logic resonates on three fronts
On the morning of September 17, MGI Tech extended its strength, opening 1.41% higher before quickly climbing, touching an intraday high of 68.83 yuan, with a maximum morning gain of 9.06%. As of the morning close, it stood at 66.40 yuan, up 5.21%. From the September 11 close of 54.32 yuan, the stock has gained 22.24% over four trading days. The broader market weakened this morning, with the Shanghai Composite Index down 0.36% and the Shenzhen Component Index down 0.29%, while the pharmaceutical and biotech sector rose 0.78% and medical devices gained 0.28%. MGI Tech led gains in both sectors, showing independent strength in a declining index environment. Capital flows showed net inflows across super-large, large, and medium orders, with only small orders seeing net outflows. On the news front, three threads point simultaneously to the AI drug discovery picks-and-shovels logic. First, on September 16, Novo Nordisk announced it would use Anthropic's Claude Science platform to accelerate new drug discovery, covering target prediction, molecule generation, and preclinical toxicity simulation. This is from the same lineage as the mRNA wave in August, when MGI Tech, as a picks-and-shovels player in the mRNA industry chain, hit the 20% daily limit on August 20 and rose another 8.22% against the trend on August 21, touching 80.50 yuan intraday. Second, GenScript provides protein expression, purification, and characterization services for Eli Lilly's TuneLab, and its AI-driven drug discovery business saw first-half revenue rise 105% year on year to about 40 million US dollars, with roughly 70% of raised funds directed to automated high-throughput wet laboratories. MGI Tech is a global pioneer among upstream life science companies in integrating three major technology platforms: full-read-length sequencing, intelligent automation, and multi-omics. It holds agent-ready automation products such as PrepALL, AlphaTool, and the AIO all-in-one system, serves more than 3,800 users worldwide, and its intelligent automation business has delivered end-to-end million-sample throughput in national-level projects such as the Beijing Brain Institute's dark laboratory. Third, Novoprotein hit the 20% daily limit today with turnover of 614 million yuan, marking two limit-up moves within four trading days. On the same day, MGI Tech announced that its subsidiary YongSheng Intelligence had reached a strategic cooperation with Changzhou Boyi Biotech, focusing on intelligent protein purification. YongSheng Intelligence relies on its self-developed ProtoPilot self-evolving multi-agent system to push protein purification from traditional automation toward an AI-driven autonomous leap. China Merchants Securities assesses that continued upstream capital investment, midstream general-purpose large models entering drug discovery scenarios, and downstream demand for high-quality wet-lab validation mean AI computing power and wet-lab validation are likely to jointly form the infrastructure of AI drug discovery, namely the picks and shovels.
688114.CG · Demand · Positive MGI Tech is the picks-and-shovels beneficiary as AI drug discovery adoption (Novo Nordisk/Anthropic, GenScript/Lilly) drives demand for its upstream life-science platforms.
Zhongji Innolight repurchases over 300 million yuan on first day; multiple A-share companies disclose buyback progress
Several A-share companies disclosed progress on share buybacks. Among them, Zhongji Innolight repurchased 374,100 shares on the first day after announcing a planned buyback of up to 8 billion yuan, paying a total of 318 million yuan. As of August 31, China Petroleum and Chemical Corporation had cumulatively repurchased 104 million A-shares for a total of 500 million yuan; Jiuzhou Pharmaceutical had repurchased 15.41 million shares for 212 million yuan; MGI Tech had repurchased 2.01 million shares for about 100 million yuan; Double Medical Technology had repurchased 6.21 million shares for 260 million yuan; Jiansheng Group had repurchased 19.25 million shares for 224 million yuan; and Bear Electric Appliance had repurchased 1.95 million shares for 65.95 million yuan.
Moderna's mRNA cancer vaccine succeeds in Phase III trial, boosting related domestic industry chain stocks
The personalized mRNA cancer vaccine Intismeran, jointly developed by Moderna and Merck, has met its primary endpoint in a Phase III clinical trial, becoming the world's first individualized neoantigen therapy and mRNA cancer treatment to achieve a positive readout in a Phase III randomized controlled study. Boosted by this news, Moderna's stock price surged 176.97 percent in a single day, and China's A-share vaccine sector saw notable movement on August 20, with Kanghua Biological and Zhifei Biological hitting their daily trading limits intraday, and Everest Medicines soaring more than 70 percent at one point. Domestic companies such as Everest Medicines, Kanghua Biological, Zhifei Biological, and MGI Tech have already made arrangements in mRNA technology platforms or underlying sequencing capabilities, but therapeutic vaccine pipelines remain in early stages, with no projects yet advancing to Phase III clinical trials. Industry insiders point out that personalized cancer vaccines involve multiple technical steps including sequencing, neoantigen selection, delivery, and individualized manufacturing. Whether overseas clinical breakthroughs can truly catalyze incremental growth in the domestic industry still depends on subsequent pipeline validation.
MGI Tech Has Repurchased 1.88 Million Shares for 93.58 Million Yuan
MGI Tech announced that as of July 31, 2026, the company had repurchased 1.88 million shares, accounting for 0.45% of total share capital, with a repurchase amount of 93.58 million yuan and a repurchase price range of 46.86 yuan to 59.21 yuan per share. In the first quarter of 2026, the company achieved revenue of 585 million yuan and a net loss attributable to the parent company of 105 million yuan.
Guofa Shares expects a net loss attributable to the parent of 11.6 million yuan in the first half of 2026
Guofa Shares disclosed its earnings forecast, expecting a net loss attributable to the parent of 11.6 million yuan in the first half of 2026, compared with a loss of 5.8417 million yuan in the same period last year. The net loss after deducting non-recurring items is expected to be 11 million yuan, compared with a loss of 6.1347 million yuan a year earlier. The company holds a 27.03 percent stake in Nanjing Huada Gongying No. 1 Venture Capital Enterprise. Affected by capital market fluctuations, the share prices of MGI Tech and YZY Biopharma held by the fund fell, causing the fund to incur losses. Investment income for the period turned from profit to loss, estimated at about negative 3.15 million yuan, compared with investment income of 7.5431 million yuan contributed by the fund in the same period last year. Sales revenue of the pharmaceutical factory's Pearl Bright Eye Drops increased by about 20 percent year on year, and the loss narrowed. However, due to market expansion falling short of expectations, revenue scale has not reached the break-even point, and it remains in a loss-making state. The Qinzhou Traditional Chinese Medicine Decoction Pieces Factory, affected by the deepening of the centralized procurement policy for Chinese medicine decoction pieces, lost market share in hospital channels for non-winning varieties, leading to a year-on-year decline in sales revenue and a decrease in net profit. The pharmaceutical distribution business, impacted by the continuous deepening of national centralized procurement and industry cost-control policies, saw an overall year-on-year decline in gross margin. At the same time, selling expenses increased year on year to stabilize market share, resulting in a year-on-year decline in net profit.
688114.CG · Capital · Negative Share price of MGI Tech held by the fund fell due to capital market fluctuations, causing investment losses for Guofa Shares.
600538.CG · Regulation · Negative Pharmaceutical distribution business impacted by national centralized procurement and cost-control policies, reducing gross margin and net profit.
MGI Tech Elects Non-Independent Director, Liu Jian Nominated
MGI Tech announced plans to increase the number of board members from 10 to 11 and nominated current general manager and legal representative Liu Jian as a candidate for non-independent director. The nomination was approved at the company's second board of directors' 25th meeting. Liu Jian's term will begin upon approval at the third extraordinary general meeting in 2026 and last until the end of the second board's term. In the first quarter of 2026, MGI Tech achieved revenue of 585 million yuan and a net loss attributable to the parent company of 105 million yuan.
China's First Ultrasound Brain-Computer Interface Company Gestalt Tech Completes 420 Million Yuan Angel+ Round
China's first ultrasound brain-computer interface company Gestalt Tech has completed a 420 million yuan angel+ round of financing. This round was led by Huaying Capital, with follow-on investments from C Capital, Sequoia China, Lens Technology, China Electronics Health Fund, Sinovation Ventures, Lingang Sci-Tech Innovation Investment, Fudan Furong Capital, and Guotai Venture Capital, among other leading domestic and international investment institutions. Existing shareholders including Daotong Investment, Yunshi Capital, Qingsong Capital, and Gobi Partners continued to oversubscribe. China Renaissance acted as the exclusive financial advisor. At the same time, Gestalt Tech's Shanghai headquarters in the Brain Intelligence Park in Minhang District was officially inaugurated. As of 14:18 on July 3, 2026, the Shanghai Stock Exchange STAR Biomedical Index rose strongly by 2.69 percent. Among constituent stocks, MGI Tech rose 14.97 percent, Dizal Pharmaceutical rose 10.77 percent, and Olym Biotech rose 8.82 percent, with stocks like Youcare Pharmaceutical and Yundong Biotech also rising. The STAR Medical ETF Huaxia rose 2.17 percent, heading for a fifth consecutive gain, with the latest price at 1.08 yuan. CICC believes that innovative fields represented by AI plus healthcare and brain-computer interfaces are experiencing rapid development, with systems from supporting policies to capital support gradually improving, and such directions may present structural investment opportunities.
格式塔科技 · Capital · Positive Completed a 420 million yuan angel+ round of financing, a significant capital event for the company.
300433.CS · Capital · Positive Participated as a follow-on investor in Gestalt Tech's financing round.
C Capital (C资本) · Capital · Positive Participated as a follow-on investor in Gestalt Tech's financing round.
CEC Health Industry Fund · Capital · Positive Participated as a follow-on investor in Gestalt Tech's financing round.
1911.HK · Capital · Positive China Renaissance acted as exclusive financial advisor for Gestalt Tech's financing round, generating advisory fee income.
688114.CG · Demand · Positive MGI Tech rose 14.97% as part of a broad rally in STAR Biomedical Index, driven by positive sentiment on AI+healthcare and brain-computer interfaces.
Sci-Tech Innovation Board Medical ETF Huaxia rises nearly 1%, institutions say pharma valuations and defensive attributes stand out
The Sci-Tech Innovation Board Medical ETF Huaxia rose 0.66%, heading for a fifth straight gain, with the latest price at 1.07 yuan. As of 1:49 PM on July 3, 2026, the Shanghai Stock Exchange Sci-Tech Innovation Board Biomedical Index surged 1.11%, with constituent Olin Bio up 8.77%, Dizal Pharmaceutical up 7.79%, and MGI Tech up 6.57%. In related news, the 12th round of national centralized drug procurement explicitly includes only mature generics, while innovative drugs still under patent protection are excluded, signaling a policy shift from cost control and price cuts to supporting and strengthening the industry. Zhongtai Securities noted that the pharmaceutical sector's valuation attractiveness and defensive attributes are prominent, with signs of bottoming and recovery emerging at the end of June, especially in CXO and innovative drugs, and recommended focusing on the internationalization of innovative drugs and CRO/CDMO performance delivery targets. The Sci-Tech Innovation Board Medical ETF Huaxia closely tracks the Shanghai Stock Exchange Sci-Tech Innovation Board Biomedical Index, which selects 50 listed companies in biomedical and related fields on the Sci-Tech Innovation Board as samples, with the top ten holdings accounting for 51.84% of the total.
STAR Market Healthcare ETF Huaxia Gains Nearly 3%; Hotgen Biotech Establishes AI Drug Company
The STAR Market Healthcare ETF Huaxia closed up 2.93 percent, marking a five-day winning streak, with the latest price at 1.09 yuan. The SSE STAR Market Biomedical Index rose strongly by 3.21 percent. Among its constituents, MGI Tech surged 13.64 percent, Hotgen Biotech gained 11.62 percent, and Dizal Pharmaceutical advanced 11.12 percent. In related news, Hotgen Biotech has officially registered and established Beijing Entropy Intelligence Pharmaceutical Technology Company, signaling the phased implementation of its AI-driven drug R&D strategy launched in 2023, and it will continue to increase investment in AI technology for innovative drug business. The STAR Market Healthcare ETF Huaxia has seen net capital inflows for five consecutive days, attracting a total of 57.85 million yuan.
China
Denmark
United States